247 related articles for article (PubMed ID: 29195024)
21. Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study.
Bengtsson K; Forsblad-d'Elia H; Deminger A; Klingberg E; Dehlin M; Exarchou S; Lindström U; Askling J; Jacobsson LTH
Rheumatology (Oxford); 2021 Jun; 60(6):2725-2734. PubMed ID: 33216939
[TBL] [Abstract][Full Text] [Related]
22. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
23. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
[TBL] [Abstract][Full Text] [Related]
24. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
25. Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study.
Lindström U; Bremander A; Haglund E; Bergman S; Petersson IF; Jacobsson LT
BMC Musculoskelet Disord; 2016 Feb; 17():106. PubMed ID: 26922375
[TBL] [Abstract][Full Text] [Related]
26. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort.
Molica Colella F; Zizzo G; Parrino V; Filosa MT; Cavaliere R; Fazio F; Molica Colella AB; Mazzone A
Adv Rheumatol; 2023 Mar; 63(1):15. PubMed ID: 36973825
[TBL] [Abstract][Full Text] [Related]
28. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
[TBL] [Abstract][Full Text] [Related]
29. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
[TBL] [Abstract][Full Text] [Related]
30. Is family history a predictor of response to tumour necrosis factor inhibitors in spondyloarthritis? A Swedish nationwide cohort study.
Morin M; Hellgren K; Lindström U; Frisell T
Scand J Rheumatol; 2022 Jan; 51(1):10-20. PubMed ID: 33755519
[No Abstract] [Full Text] [Related]
31. Psoriatic arthritis and spondyloarthritis assessment and management update.
Mease P
Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry.
Mease PJ; Blachley T; Malatestinic WN; Harrold LR; Dube B; Lisse JR; Bolce RJ; Hunter TM
Curr Med Res Opin; 2024 Feb; 40(2):315-323. PubMed ID: 38050693
[TBL] [Abstract][Full Text] [Related]
34. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
35. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
36. Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Walsh JA; Pei S; Alexander S; Braaten T; Walker JH; Clewell J; Douglas KM; Penmetsa GK; Ye X; Breviu B; Cannon GW; Kunkel GA; Sauer BC
Semin Arthritis Rheum; 2024 Jun; 66():152436. PubMed ID: 38714073
[TBL] [Abstract][Full Text] [Related]
37. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
Chan J; Gladman D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
[TBL] [Abstract][Full Text] [Related]
38. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
[TBL] [Abstract][Full Text] [Related]
39. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
40. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
